Curative Insurance Company adds GRAIL’s Galleri test to member benefits

Healthcare services company Curative announced the availability of Galleri, a multi-cancer early detection screening test to eligible insurance plan members.

The Galleri test will be available to all members, across all plan types, who are over the age of 50 and to all other members with risk factors for developing cancer. The Galleri test is part of a list of benefit offerings available for $0 copay and $0 deductible on Curative’s health insurance plan.

With a simple blood draw used in addition to current single-cancer screenings, Galleri claims that it can identify DNA shed by cancer cells to help screen for some of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver and others.

“We are excited to be working with GRAIL and proud to offer Curative health plan members the groundbreaking Galleri test that is truly key in helping detect cancer early on for our members. Preventive care is at the core of our health insurance plan, and the Galleri test may allow qualified members to screen for potential cancer early, before any symptoms appear when it may be more easily treated and potentially curable. This is not just about early detection; it’s also about empowering our members with the tools to be proactive with their health. Curative’s partnership with GRAIL is a testament to our commitment to preventive care and the well-being of our members.” – Fred Turner, CEO and co-founder of Curative.

“Single-cancer screenings play an important role in detecting five specific cancers today. However, nearly 70% of deaths are caused by cancers that don’t have recommended screenings. By providing the Galleri test to eligible health insurance members, Curative is helping to screen for the deadliest cancers that often come with no warning today, demonstrating their commitment to preventative and proactive care.” – Bob Ragusa, CEO at GRAIL.